Condition: Polycythemia Vera · Sponsor: Ono Pharmaceutical Co., Ltd.
The purpose of this study is to evaluate the efficacy and safety of sapablursen when added on to current standard of care (SOC) for Polycythemia Vera (PV) therapy. The study will be conducted in three sequential parts (Part 1a blinded treatment, Part 1b open-label treatment, \& Part 2 long-term extension). Participants may receive treatment for up to 156 weeks.
This description comes directly from the study's public registry record.
Clinical Team · 888-724-3274 · clinicaltrials@deciphera.com
Always discuss trial participation with your own doctor first.
| Regis Clinical Research LLC. | Miami, Florida, United States | Recruiting |
| Florida Clinical Trials Group | Plantation, Florida, United States | Recruiting |
| Florida Clinical Trials Group | Tamarac, Florida, United States | Recruiting |
| The Center for Cancer & Blood Disorders | Bethesda, Maryland, United States | Recruiting |
| Montefiore Medical Center | The Bronx, New York, United States | Recruiting |
| Gabrail Cancer Center Research | Canton, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07429266